Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.42 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.42 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.42 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.42 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.41 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.40 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.40 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.40 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6972673 | 1.00 | MAPT (0.45) | MAPTLMNAPMP22HTR1ADRD2 | |
| SCHEMBL6974927 | 0.92 | DRD2 (0.49) | MAPTHTR1ADRD2ADRA2AADRA2C | |
| SCHEMBL6960133 | 0.82 | DRD2 (0.58) | MAPTLMNAHTR1ADRD2ADRA2A | |
| SCHEMBL9014693 | 0.80 | SIGMAR1 (0.55) | HTR1ADRD2ADRA2AADRA2CADRA1D | |
| Hydrochloric Acid SCHEMBL10407883 | 0.77 | KCNH2 (0.50) | MAPTHTR1ADRD2ADRA2AADRA2C | |
| SCHEMBL7402139 | 0.76 | DRD2 (0.69) | MAPTHTR1ADRD2ADRA2AADRA2C | |
| SCHEMBL7812153 | 0.75 | HTR1A (0.63) | HTR1ADRD2ADRA2AADRA2CADRA1D | |
| Hydrochloric Acid SCHEMBL7408947 | 0.75 | DRD2 (0.67) | HTR1ADRD2ADRA2AADRA2CADRA1D | |
| SCHEMBL9052228 | 0.75 | DRD2 (0.47) | MAPTLMNAHTR1ADRD2ADRA2A | |
| SCHEMBL7405539 | 0.75 | ALDH1A1 (0.53) | MAPTLMNAHTR1ADRD2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946538-B1 | INDANE OR DIHYDROINDOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2003-08-06 | — | — | EP | disclosed |
| US-6436940-B1 | — | — | 2002-08-20 | — | — | US | disclosed |
| US-6436940-B2 | COMBINED EFFECTS OF DOPAMINE D4 RECEPTOR LIGANDS AND SEROTONIN REUPTAKE INHIBITORS; SCHIZOPHRENIA; ANTIDEPRESSANT; ANXIOLYTIC AGENTS; PSYCHOLOGICAL DISORDERS; PANIC, SLEEP AND OBSESSIVE COMPULSIVE DISORDERS; ANTIISCHEMIC AGENTS | H. LUNDBECK A/S (DK) | 2002-08-20 | — | — | US | disclosed |
| US-6331544-B1 | TREATING POSITIVE AND NEGATIVE SYMPTOMS OF SCHIZOPHRENIA AND OTHER PSYCHOSES | H. LUNDBECK A/S (DK) | 2001-12-18 | — | — | US | disclosed |
| US-20010051625-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-12-13 | — | — | US | disclosed |
| EP-0946538-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028290-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051625-A1 | Indane or dihydroindole derivatives | DRD2, SLC6A3, DRD1 | HTR1A 16/4885DRD2 1/4885ADRA2A 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.